Efficacy and Safety Study of STX209 (Arbaclofen) for Social Withdrawal in Adolescents and Adults With Fragile X Syndrome
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
To explore the efficacy, safety and tolerability of STX209 (arbaclofen) administered for the
treatment of social withdrawal in adolescents and adults with fragile X syndrome (FXS)